



Quels enjeux, quels besoins pour l'imagerie de population

Bernard MAZOYER: GIN, UMR5296, Univ de Bordeaux

Pierre MOUILLARD: CEO VIGISYS

Jean-Gabriel GANASCIA: Univ UPMC, Lab. ACASA


Animé par:

Christian Barillot, Jean-François Chateil, Michel Dojat

October the 12th, 2015

France Life Imaging

1







- Objectives of the Node:
 - Specify and set up an hardware and software infrastructure for the management and processing of in-vivo images
 - Elaborate and implement usage scenarios of the infrastructure
 - Set-up an operational structure to operate the infra that can be self-funded from internal seed funding
 - For:
 - The Clinician: to conduct large and/or clinical and preclinical research studies involving new innovative in-vivo medical imaging and new innovative therapeutic procedures
 - The Pharma: to provide pharma and CRO companies high technological computational solutions in in-vivo imaging
 - The medical imaging community: to allow experimentation and validation of new innovative in-vivo imaging solutions
- · Strengths: Based on high technological expertise and experience from
 - Medical Imaging Laboratories form the FLI regional nodes
 - Top national technological teams in medical imaging: INRIA (Rennes, Sophia), CNRS (ICUBE, I3S), INSERM (Brest, Nancy), bringing:
 - ArchiMed, CATI-DB, SHANOIR for data management solutions
 - BrainVisa, MedInria, VIP platform for medical image processing solutions
 - Large national clinical cohorts: CATI, OFSEP, ...





Information Analysis and Management - IAM (2)



- FLI-IAM: a two-Stages process
 - Initial stage (2013-2016):
 - Set up of the infrastructure including specification of the needs of the various categories of users, the definition of the roadmap for the development and operation of the infrastructure
 - Pilot phase on a limited number of in vivo imaging application domains for clinical and preclinical research
 - Operational stage (2017 and onward):
 - Open call to select public/private management and exploitation providers of the developed infrastructure (including SME)
 - Extend the infrastructure to broaden the range of clinical and preclinical research application domains
 - Extend the range of software integration by providing open interoperability standards with conformal statements



